Prostate News and Research

RSS

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

The Canadian Cancer Society British Columbia and Yukon today called on the B.C. government to enact legislation to ban the cosmetic use of pesticides that would set a new national standard. The Society is also asking British Columbians to participate in the on-line public consultation.

8 Jan 2010

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Prostate Cancer

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Prostate Cancer to reflect new recommendations regarding active surveillance, also referred to as watchful waiting, for men with low risk prostate cancer.

8 Jan 2010

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

7 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Author evaluates potential benefits of IAD for treating prostate cancer

'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

5 Jan 2010

Androgen receptor plays critical role in wound healing

A molecular receptor pivotal to the action of male hormones such as testosterone also plays a crucial role in the body's ability to heal, report scientists in the December issue of the Journal of Clinical Investigation.

5 Jan 2010

AP series examines worldwide impact of drug resistance

The Associated Press reports on how the misuse of drugs worldwide has contributed to drug-resistant diseases in a series of articles following a six-month investigation by the news service.

5 Jan 2010

EPO approves Advaxis patent application for Listeria Antigens

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled “Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens,” has been granted and will be issued as patent #1032417

4 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Sharing Miracles: A TV program that features inspirational stories of real patients

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

31 Dec 2009

AUA experts urge to focus on urologic health conditions in upcoming year

This new year, make a resolution to improve your health and talk to your doctor about urologic conditions. Although urologic problems may seem embarrassing to talk about, these conditions are more common than you think and a delay in seeking medical attention could cause you unnecessary stress, prolong the problem and even increase your risk for a more serious condition.

30 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

Prostate News and Research

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Prostate Cancer

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

U.S. market for urological devices to reach over $5.4 billion in 2016

Author evaluates potential benefits of IAD for treating prostate cancer

Androgen receptor plays critical role in wound healing

AP series examines worldwide impact of drug resistance

EPO approves Advaxis patent application for Listeria Antigens

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Sharing Miracles: A TV program that features inspirational stories of real patients

AUA experts urge to focus on urologic health conditions in upcoming year

TRAP-1 may prevent cancer cell death, current research suggests

Phase 3 trial of figitumumab discontinued by Pfizer

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Study suggests routine evaluation does not predict prostate cancer

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News